SCYNEXIS Presents Data at Superbugs and Superdrugs 2018

Pre-clinical data demonstrates inhibitory activity of SCY-078 against C. auris Two ongoing trials – FURI and CARES – to study oral SCY-078 in patients with refractory fungal infections, including C. auris JERSEY CITY, N.J. , March 20, 2018 /PRNewswire/ — SCYNEXIS, Inc.

READ FULL TEXT

Leave a Reply

Your email address will not be published.